CJC-1295 (NO DAC) – 5mg

Research Applications:

GHRH Receptor Signaling

CJC-1295 is a modified growth hormone-releasing hormone analog used in endocrine research to study GHRH receptor activation and pituitary GH-axis signaling. This row is written for the without DAC version of the product [1].
The compound family is useful in receptor-activation studies where researchers compare GH release, IGF-1 response, and feedback regulation under defined experimental conditions.

Pharmacokinetic Comparison Models

CJC-1295 formulations are often differentiated by half-life and binding strategy. In catalog content, the key research distinction is whether the design supports shorter pulse-style experiments or longer exposure models.

Secretagogue and Endocrine Panel Design

CJC-1295 can be compared with ipamorelin, tesamorelin, or related secretagogues to map receptor-specific and combined pathway outputs. No human-use claims are inferred.

Referenced Citations:

1. CJC-1295 pharmacokinetics and GH response
   Source: PubMed-indexed study used by existing CJC/Ipamorelin product content.
2. Existing Nuvora CJC-1295 / Ipamorelin content
   Source: Existing site content used for style and GH-axis context.